SEC Form 4 filed by Director Goggins Colleen A

$IQV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $IQV alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOGGINS COLLEEN A

(Last) (First) (Middle)
C/O IQVIA HOLDINGS INC.
2400 ELLIS ROAD

(Street)
DURHAM NC 27703

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IQVIA HOLDINGS INC. [ IQV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Shares (1) 02/05/2025 A 170 (1) (1) Common Stock 170 $205.44 4,118 D
Explanation of Responses:
1. Each deferred share is convertible into one share of common stock of IQVIA Holdings Inc. (the "Issuer") upon settlement. The deferred shares become settleable, in accordance with the Issuer's Non-Employee Director Deferral Plan, when the reporting person ceases to be a director, upon a change in control of the Company, or upon death of the reporting person. There is no expiry date.
Remarks:
/s/ Matthew Gilmartin, Attorney-in-Fact for Colleen A. Goggins 02/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $IQV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IQV

DatePrice TargetRatingAnalyst
2/3/2025Buy → Neutral
BTIG Research
12/20/2024$250.00Overweight
Stephens
10/14/2024Buy
Redburn Atlantic
9/4/2024$275.00Outperform
RBC Capital Mkts
7/24/2024$266.00 → $242.00Buy → Hold
Jefferies
6/6/2024$270.00Buy
Goldman
2/26/2024$290.00Outperform
Leerink Partners
2/15/2024Buy → Neutral
Guggenheim
More analyst ratings

$IQV
Press Releases

Fastest customizable press release news feed in the world

See more
  • IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

    IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the "Leaders" category of the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. IDC, a global provider of market intelligence, says in its report: "Consider IQVIA when seeking deep clinical and DCT implementation strategy expertise across therapeutics areas and phases, with over 200 DCT consultants, a wide portfolio of DCT-enabling technologies and services, and expertise in providing inputs on country-wise regulato

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

    IQVIA Laboratories, a leading global drug discovery and development laboratory services organization, announces the launch of Site Lab Navigator, an advanced suite of solutions that automates and streamlines lab workflows for clinical trial sponsors and investigator sites. At the core of Site Lab Navigator is a new, innovative e-Requisition solution, which allows investigator sites to submit requisitions and manage lab specimens electronically, eliminating the need for manual, paper-based processes. This reduces administrative burden, minimizes errors, drives compliance and improves study execution for both sponsors and investigator sites. IQVIA Laboratories' e-Requisition solution with

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questions. Using a conversational interface with advanced data science, it makes complex analytics accessible to a wide variety of users and provides near real-time insights. IQVIA AI Assistant builds upon IQVIA's decade of experience in artificial int

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$IQV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IQV
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$IQV
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$IQV
SEC Filings

See more

$IQV
Leadership Updates

Live Leadership Updates

See more
  • IQVIA Appoints Richard Staub III President of Research & Development Solutions

    IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions

    IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$IQV
Financials

Live finance-specific insights

See more
  • IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance

    Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, part

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day

    Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca

    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$IQV
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more